The Novartis Malaria Initiative

For over a decade, the Novartis Malaria Initiative has been a pioneer in the fight against malaria. Focused on access, treatment, R&D and capacity building, the initiative is the largest access-to-medicine program within Novartis measured by the number of patients reached annually. Together with our partners, and with our continued patient-centric approach, we are committed to the common goal of malaria elimination.

Content from this campaign

Health & Healthcare

Novartis Renews Commitment to Malaria Elimination, Investing USD 100 Million to Research and Develop Next-generation Antimalarials
Novartis announces a five-year commitment to the fight against malaria in conjunction with the 7th Multilateral Initiative on Malaria Conference and the Malaria Summit of the Commonwealth Heads of Government meeting. Further, the company releases new African research on progress and remaining challenges toward the 2030 malaria elimination targets, together with Elimination 8 and the KEMRI-Wellcome Trust program.

Health & Healthcare

Novartis and Medicines for Malaria Venture Launch Patient Trial in Africa for KAF156, a Novel Compound Against Multidrug-resistant Malaria
Novartis and Medicines for Malaria Venture (MMV) have launched a patient trial for KAF156, a next-generation antimalarial compound with the potential to treat drug-resistant strains of the malaria parasite.

Health & Healthcare

Malaria Fighter Rides Bicycle into Battle with Disease, Story from Novartis
Healthcare worker Dismus Mwalukwanda is on the front line of the battle against malaria. Saving lives is his priority

Dismus Mwalukwanda works on the front line of the battle against malaria, one of the world’s deadliest diseases. He’s a community healthcare worker responsible for testing and treating patients in a remote part of rural Zambia, as well as teaching people how to combat the illness.

Health & Healthcare

Novartis Story About the Rising Concern of Malaria That Resists Treatment
In Kenya, about three-quarters of the population is at risk for malaria, and all four species of the malaria parasite that infect humans occur in the country. Although there has been substantial progress, malaria remains the leading cause of mortality in Kenya, killing an estimated 30,000 people every year, most of them children under 5 years old.

Health & Healthcare

Novartis Story Celebrates a Life Dedicated to Fighting Malaria
In Kenya, about three-quarters of the population is at risk for malaria, and all four species of the malaria parasite that infect humans occur in the country. Although there has been substantial progress, malaria remains the leading cause of mortality in Kenya, killing an estimated 30,000 people every year, most of them children under 5 years old.

Health & Healthcare

Lessons from Malaria Can Help Fight Against Antimicrobial Resistance
Two weeks ago, G20 leaders committed to working together to address one of the world’s most pressing and perplexing security threats: antimicrobial resistance (AMR) – a fierce and evolving adversary against which conventional therapeutic weapons are of no use.

Philanthropy & Cause Initiatives

Partnering to Counter the Threat of Drug-resistant Malaria

Events, Media & Communications

Watch: Together We Can End Malaria for Good - New Videos from Novartis Mark World Malaria Day
The fight against malaria continues to advance, led by the hard work of countless people. On World Malaria Day, meet some of the faces behind the Novartis Malaria Initiative and listen to their stories.

Philanthropy & Cause Initiatives

The Specter of Malaria That Resists Treatment, New Photo Essay from Novartis
The fight against malaria continues to advance, led by the hard work of countless people who head out every day to their communities with a firm belief that they can make a difference. On World Malaria Day, a new photo essay from Novartis presents a collection of scenes on the ground.

Innovation & Technology

Novartis Launches SMS for Life 2.0 in Nigeria to Help Improve Access to Essential Medicines
Novartis announced today the launch of an innovative technology-based healthcare program called SMS for Life 2.0 in Kaduna State, Nigeria. The program aims to increase the availability of essential medicines and improve care for patients across the region by using simple, available, and affordable technology. SMS for Life 2.0 is a joint public-private partnership led by Novartis and supported by its partners, the Kaduna State Ministry of Health and Vodacom.
Novartis logo

More from Novartis

  1. Novartis US Foundation commits $25M to improve health equity by reducing health disparities in the US
    Building on $10M+ commitments to date, US Foundation is providing up to an additional $15M due to emergence of COVID-19 pandemic and elevated focus on...

  2. Novartis US Foundation
    Initiatives summarizing efforts from the Novartis US Foundation.

  3. Novartis COVID-19 Trials
    Novartis clinical trial efforts in COVID-19 R&D.

  4. Novartis US Foundation COVID-19 Response
    In response to the COVID-19 pandemic in the US, the Novartis US Foundation established a Response Fund, which will provide USD 5 million over a one...

  5. Novartis – science based innovation for better patient outcomes
    Novartis is a global healthcare company based in Switzerland that provides solutions to address the evolving needs of patients worldwide.

  6. Novartis Foundation Leprosy Elimination Initiative
    The Novartis Foundation is convening experts from the global health and anti-leprosy community to discuss the current state of leprosy treatment and...

  7. Novartis Access: Medicines to treat chronic diseases in lower-income countries
    Novartis recently announced the launch of the Novartis Access Portfolio, a first-of-its-kind portfolio approach in healthcare industry, aiming to...

  8. The Novartis Malaria Initiative
    For over a decade, the Novartis Malaria Initiative has been a pioneer in the fight against malaria. Focused on access, treatment, R&D and capacity...